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Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA ;
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ABSTRACT
Background. The use of cannabis and other illicit drugs (OIDs) and their co-morbid misuse are
frequently reported in the literature. Correlated vulnerabilities and causal or gateway inﬂuences
have been implicated in this association. We investigated the source of this co-morbidity between
cannabis use (experimentation, early and repeated use, and problems) and OID experimentation
and problems using genetic models proposed by Neale and Kendler (American Journal of Human
Genetics 1995, 57, 935–953).
Method. In a sample of 4152 same-sex male and female adult Australian twin individuals, we ﬁt
13 genetically informative models of co-morbidity to data on experimentation, early use, repeated
use of cannabis and co-morbid OID experimentation, and to abuse/dependence (A/D) problems
with cannabis and OIDs.
Results. Model-ﬁtting results suggest that common genetic, shared and unique environmental
factors are responsible for the association between cannabis experimentation, early use, repeated
use and A/D problems and OID experimentation or problems. The liability causation model, which
is a reduced form of the correlated vulnerabilities model, also ﬁt very well. In women, we found
evidence for high-risk cannabis experimenters and repeated users to be at increased risk for
OID experimentation, despite being below the risk threshold on the liability distribution for OID
experimentation (extreme multiformity).
Conclusions. Co-morbid cannabis and OID use and misuse are due partly to a common predisposition to substance use disorders. Putative causal eﬀects could not be ruled out. These models
warrant further research, so that features of the correlated vulnerabilities model and the gateway
models can be studied jointly in a single series of adaptive nested models.

Two predominant theories have been proposed
to explain this relationship. First, the ‘gateway ’
theory posits that (i) cannabis use occurs prior
to OID use (sequence) and (ii) cannabis users
are at increased risk for using OIDs (association), to argue that cannabis use may have a
causal inﬂuence on subsequent use or misuse of
OIDs (causation) (Kandel, 2003). Second, the
correlated vulnerabilities theory suggests that
users of cannabis subsequently use OIDs because of a general predisposition to illicit drug

INTRODUCTION
Results from epidemiological studies suggest
that cannabis users are more likely to subsequently use other illicit drugs (OIDs), such as
cocaine, hallucinogens, non-prescription sedatives, stimulants and opiates (Kandel, 2002).
* Address for correspondence: Arpana Agrawal, Ph.D.,
Washington University School of Medicine, Department of
Psychiatry, 660 S. Euclid, Box 8134, St Louis, MO 63110, USA.
(Email : arpana@wustl.edu)
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use, or more globally to deviant behavior,
including conduct disorder (MacCoun, 1998 ;
Morral et al. 2002 a, b).
Early family studies found evidence for the
clustering of illicit drug abuse amidst family
members (Bierut et al. 1998 ; Merikangas et al.
1998). Multivariate twin analyses, such as those
by Kendler and colleagues, have also shown
that a common genetic factor is responsible for
the genetic covariation across use and abuse/
dependence (A/D) of several classes of illicit
drugs, including cannabis (Karkowski et al.
2000 ; Kendler et al. 2003). While these genetic
analyses supported the correlated vulnerabilities
hypothesis, the preceding genetic analyses did
not posit or test plausible alternative mechanisms for the association between cannabis and
OIDs. Subsequent twin modeling did contrast
varying interpretations of a correlated vulnerabilities model with some version of a ‘ gateway ’
or ‘causal ’ model (Tsuang et al. 1998; Lynskey
et al. 2003; Agrawal et al. 2004 c; Lessem et al.
2006 ; Lynskey et al. 2006) and consistently
found overwhelming support for shared genetic
risk factors contributing to the co-morbidity
between cannabis and OID involvement. However, with the exception of Tsuang et al. (1998),
who showed that their version of the gateway
model provided an inferior ﬁt to data on A/D
of cannabis and OIDs when compared to a
common liabilities model, in Vietnam era male
twins, the remaining genetically informative
studies have not been able to unequivocally rule
out all gateway-like inﬂuences.
Four of the remaining studies used a co-twin
control design to test whether an early-onset
cannabis-using member of a twin pair was more
likely to subsequently use OIDs when compared
to their co-twin who was not an early-onset
cannabis user. Lynskey et al. (2003, 2006),
Agrawal et al. (2004 b) and Lessem et al. (2006)
all found evidence for a relationship between
cannabis and OID use that extended beyond
their association due to correlated familial
(genetic and familial environmental) factors
and could be reﬂective of causal inﬂuences
or correlated environmental risks. However,
none of these studies examined alternative formulations of correlated vulnerabilities and
gateway models, which were tested by Agrawal
et al. (2004 c), and showed that while the correlated liabilities model ﬁt their data from adult

twin pairs from Virginia very well, a ‘gateway’
model, which was non-causal, also ﬁt the data
well, thus highlighting the need for a more
rigorous test of plausible genetic mechanisms
contributing to the association between cannabis and OID involvement.
One of the criticisms of epidemiological tests
of the ‘ gateway ’ theory is that true causality
cannot be extricated from covariation due to an
unmeasured third correlated variable (Kandel,
2003). This is to say that, if an unmeasured
environmental risk factor, such as a traumatic
event, is a predictor of both cannabis and OID
use and misuse, then even in traditional twin
studies, where this unmeasured environmental
inﬂuence will be unique to each member of
the twin pair, but common across traits, this
third variable’s eﬀects may be confounded
with truly causal inﬂuences. However, even
operating within the restrictive framework of
cross-sectional twin data, we can test a series
of possible mechanisms by which genetic and
environmental risk factors contribute to the
association between cannabis and OID use
patterns.
Neale & Kendler (1995) proposed a series of
13 genetically informative models (NK models)
that address the primary hypothesis of whether
two disorders (in our case, cannabis and OID
use, or problems) are truly etiologically distinct
and, if not, then what are the possible mechanisms that govern the co-occurrence of these two
disorders ? Based on the co-morbidity models
of Klein & Riso (1994), the NK models include
seven main models and six submodels (Table 1).
The simplest of these models tests the null
hypothesis that cannabis and OID experimentation (we use these traits here for illustrative
purposes) have distinct non-overlapping vulnerabilities, inﬂuenced by uncorrelated genetic and
environmental inﬂuences. Therefore, according
to the chance model (Model 1), the observed
co-occurrence of cannabis and OID experimentation is due to chance alone. In the alternate
forms model (Model 2), a single underlying
liability governs both cannabis and OID experimentation. Models 3–8 use the concept of
multiformity, where a proportion of individuals
above a certain threshold for, say cannabis
experimentation, are at increased risk for experimenting with OIDs, even if they are below
the threshold for OID experimentation itself.

Genetic co-morbidity models for cannabis and other illicit drugs

Table 1.
Model
number

Brief description of each Neale–Kendler co-morbidity model, using lifetime co-morbid
cannabis and other illicit drug (OID) experimentation as an example
Model

1
2

Chance
Alternate forms

3

Random
multiformity

4
5
6

Extreme
multiformity

7
8
9
10
11
12
13
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Three independent
disorders
Correlated
vulnerabilities
Liability causation

Submodels

Description

—
—

Co-morbid cannabis and OID experimentation occurs due to stochasticity
Single liability : a proportion of individuals experiment with cannabis
and a proportion experiment with OIDs
Independent liabilities : a proportion of cannabis experimenters are OID
experimenters, and vice versa
A proportion of cannabis experimenters are OID experimenters, even when
below the threshold for OID experimentation
A proportion of OID experimenters are cannabis experimenters, even when
below the threshold for cannabis experimentation
Independent liabilities : a proportion of high-risk cannabis experimenters
are OID experimenters, and vice versa
A proportion of high-risk cannabis experimenters are OID experimenters,
even when below the threshold for OID experimentation
A proportion of high-risk OID experimenters are cannabis experimenters,
even when below the threshold for cannabis experimentation
Three independent liabilities for cannabis use, OID and cannabis use
co-morbid with OID
Correlated liabilities : correlation between latent genetic and environmental
inﬂuences on cannabis use and OID experimentation
Independent liabilities : liability to experiment with cannabis has causal
inﬂuence on liability to experimentation with OIDs, and vice versa
Liability to experiment with cannabis has causal inﬂuence on liability to
experiment with OIDs
Liability to experiment with OIDs has causal inﬂuence on liability to
cannabis experimentation

Random multiformity
of cannabis
Random multiformity
of OIDs
—
Extreme multiformity
of cannabis
Extreme multiformity
of OIDs
—
—
Reciprocal causation
Unidirectional :
cannabis to OIDs
Unidirectional :
OID to cannabis

This multiformity can be random, with one
threshold (Models 3–5), or extreme, with one
low- and one high-risk threshold per trait
(Models 6–8). We propose that the multiformity
models may be well suited to a test of ‘gatewaylike ’ mechanisms. In other words, these models
allow for an increased risk for OID experimentation in cannabis experimenters who are
otherwise not vulnerable to OID experimentation. Hence, this increased risk, which is not
due to correlated risk factors, is reﬂective of the
direct inﬂuence of cannabis experimentation
on OID experimentation. Model 9 models
three independent disorders, where co-morbid
cannabis and OID experimentation are governed by a unique liability distribution, such
that a unique set of risk factors inﬂuence the
liability to co-morbid experimentation. The
correlated vulnerabilities hypothesis (Model 10)
tests whether shared genetic and environmental
risk factors inﬂuence co-morbid cannabis and
OID experimentation. Finally, the liability
causation models (Models 11–13), where the
liability to experiment with cannabis is regressed
on the liability to experiment with OIDs and
vice versa, test whether individuals who are at

risk for cannabis experimentation are also more
vulnerable to OID experimentation. Although
these models appear to test causality, they are
more similar to the correlated vulnerabilities
model in that they allow for the composite
liability to OID experimentation to be inﬂuenced
by the individual’s liability to experiment with
cannabis. Diagrammatic representations may be
found in related publications (Neale & Kendler,
1995; Rhee et al. 2005).
While these models may not represent the
entire gamut of possible sources of covariation
between cannabis and OID use patterns, they
are a fairly comprehensive series of comparisons
of bivariate twin models for co-morbid drug
use disorders and represent a highly informative
addition to the extant literature on the comorbidity between cannabis and OID involvement. Therefore, in the present study, using a
large sample of adult Australian twins, we tested
the 13 NK models of co-morbidity to investigate
the co-morbidity between: (i) experimentation
with cannabis and OIDs; (ii) early use of cannabis and OID experimentation ; (iii) repeated
use of cannabis and OID experimentation ; and
(iii) A/D problems with cannabis and OIDs.
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METHOD
Sample
For this study, we used data from 1748 male
[487 monozygotic (MZ) and 387 dizygotic (DZ)
pairs] and 2404 female (696 MZ and 506 DZ)
adult twins from same-sex pairs who were
members of the younger cohort of the
Australian Twin Registry. As the current formulation of the models require the construction
of twin–co-twin frequency tables, only data
from these complete pairs of twins were used.
We did not ﬁnd signiﬁcant diﬀerences in rates
of cannabis (x2=0.03) or OID experimentation
( x2=0.56) or in cannabis (x2=2.38) or OID
( x2=2.30) problems based on whether a twin
was from a complete pair or a singleton. Twin
pairs were aged 24–36 years at the time of
interviews conducted in 1996–2000. All twins
were born between 1964 and 1971 and were
initially recruited through the Australian school
systems and by mass media appeals. Parents
initially registered the adolescent twins in 1980–
1982 and the twins themselves were mailed a
questionnaire in 1989–1992, when the twins
were aged 18–25 years, and subsequently reinterviewed by telephone in 1996–2000, after
informed consent, as approved by the Institutional Review Boards of the Washington
University in St Louis, USA and the Queensland
Institute of Medical Research, Australia, was
obtained from all participants. Further details
regarding sample ascertainment and collection
are presented in related publications (Heath
et al. 2001 ; Lynskey et al. 2003).
Measures
(1) Experimentation with cannabis : participant
reported having used cannabis at least once
in their lifetime.
(2) OID experimentation : participant reported
experimenting with either cocaine or sedatives (e.g. barbiturates) or stimulants (e.g.
Ritalin) or opiates (e.g. codeine, heroin) or
hallucinogens (e.g. LSD).
(3) Early-onset cannabis use : participant reported initiation of cannabis use prior to age
17. This cut-oﬀ has previously been used in
adult samples to denote early use (Lynskey
et al. 2003 ; Agrawal et al. 2004b).
(4) Repeated cannabis use : participant endorsed
using cannabis 11 or more times in their life.

This cut-oﬀ aﬀorded us suﬃcient cell sizes
for twin analyses.
(5) Cannabis A/D problems: participant endorsed one of the following A/D problems
from a non-diagnostic section of the interview :
(a) use of drug for more days/greater
quantities than intended ;
(b) needed larger amounts of drug to get
same eﬀect or could not get high on
amount used ﬁrst few times ;
(c) being under inﬂuence of drug in hazardous situations (e.g. when driving a
car, using machinery) ;
(d) being under the inﬂuence or after-eﬀects
of drug has interfered with household/
work responsibilities ;
(e) emotional or psychological problems
due to use of drug;
(f) wanted to cut back on use of drug three
or more times in life.
(6) OID A/D problems : participant reported
A/D problems separately for cocaine, sedatives, stimulants, opiates and hallucinogens
and A/D problems with any one drug class
constituted OID problems.
The prevalence of cannabis experimentation,
early use, repeated use and problems, and OID
experimentation and problems are shown in
Table 2.
Twin models
Data from MZ and DZ twin pairs allowed us to
partition the total variance in use (experimentation, early use and repeated use) and A/D
problems of cannabis and OID experimentation
and problems into three sources : additive
genetic (or A), shared environmental (or C) and
unique environment (or E) (Neale & Cardon,
1992). Additive genetic inﬂuences are shared
100 % and 50% between members of an MZ
and DZ twin pair respectively while shared
environmental inﬂuences are shared 100 %
between members of a twin pair, irrespective of
zygosity (under the equal environments assumption). Unique environmental inﬂuences also
include measurement error and are not shared
between members of a twin pair. Heritability
refers to the proportion of the total variance

Genetic co-morbidity models for cannabis and other illicit drugs

Table 2. Prevalence of cannabis experimentation, early use, repeated use and problems and
other illicit drug (OID) experimentation and
problems in male and female Australian twins
Men
(n=1748)
(%)

Women
(n=2404)
(%)

Cannabis
Experimentation
Early use
Repeated use
Problems

69
28
40
28

53
18
22
15

Other illicit drugs (OIDs)
Experimentation
Problems

47
8

37
5

that is due to genetic factors (Sham, 1998). To ﬁt
models to dichotomous twin data, the assumption of an underlying normal distribution is
made. It is assumed (as it cannot be tested for
dichotomous outcomes) that all individuals in
the given population lie along a continuous
normally distributed spectrum of vulnerability
and that manifesting the trait (or phenotype)
occurs when an individual falls above a speciﬁc
threshold of risk that is imposed upon this
underlying distribution.
The model-ﬁtting procedure included ﬁtting
all 13 models separately in males and females for
(i) co-morbid experimentation with OIDs and
cannabis, (ii) co-morbid experimentation with
OIDs, with early cannabis use, (iii) co-morbid
experimentation with OIDs, with repeated
cannabis use, and (iv) co-morbid A/D problems
with OIDs and cannabis. To reduce the total
number of hypotheses tested, quantitative
gender diﬀerences were only examined for two
best-ﬁtting models. The statistical software
package Mx allows for the NK models to be
ﬁtted using observed twin–co-twin frequencies
(Neale, 2004). Twins were cross-tabulated by
their co-twin’s drug experimentation, by zygosity, and the observed frequencies were compared with frequencies expected under each of
the 13 NK models, to arrive at a x2 ﬁt statistic.
Models were not nested (although submodels
were nested within their main model) and comparison of ﬁt was made using the Akaike
Information Criterion (AIC), which is an index
of both ﬁt and parsimony (Akaike, 1987;
Williams & Holahan, 1994).
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RESULTS
The tetrachoric correlations between experimentation with cannabis, early cannabis use
and repeated cannabis use, with experimentation with OIDs, were 0.64, 0.53 and 0.75 respectively. The tetrachoric correlation between
cannabis A/D problems and A/D problems with
OIDs was also high (0.68).
Table 3 shows the AIC (model-ﬁt statistic)
for co-occurring experimentation of OID with
experimentation, early use and repeated use
of cannabis and for cannabis and OID A/D
problems. Models were ﬁt separately in male
and female same-sex twin pairs for co-occurring
use (experimentation, early and repeated use) of
and co-occurring problems with cannabis and
OIDs. The models are ranked for each set of
phenotypes as best-ﬁtting (1) and second-bestﬁtting (2) model. When comparing nested submodels, only the best-ﬁtting nested model is
ranked (e.g. if both the reciprocal causation and
unidirectional causation of cannabis model
have low AIC values, the submodel with the
lower AIC is selected as best-ﬁtting). Table 4
shows the standardized parameter estimates for
the best-ﬁtting models, separately for males and
females. Constraining variance components
across genders did not result in a signiﬁcant deterioration of ﬁt in the best-ﬁtting and secondbest-ﬁtting models, although thresholds could
not be equated across male and female twins.
However, as in some instances the best-ﬁtting
model (or submodel) was diﬀerent for males and
females, we present gender-speciﬁc estimates in
Table 4.
Overall, cannabis experimentation, early use,
repeated use, A/D problems, and also OID
experimentation and A/D problems were signiﬁcantly heritable (Table 4). For cannabis,
A/D problems were more strongly inﬂuenced by
additive genetic factors than experimentation
or early use, while the heritability of repeated
cannabis use was comparable to that for
cannabis A/D problems. Shared environmental
factors contributed to the total variance across
a majority of the phenotypes, with the exception
of repeated cannabis use in both sexes, and OID
A/D problems in male twins only.
Table 3 shows that the correlated vulnerabilities model and the related models of liability causation were the best-ﬁtting models for
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Table 3. The Akaike Information Criterion (AIC)a is presented for the 13 co-morbidity models, ﬁtted
separately to data on cannabis experimentation, early (before 17 years) use, repeated use (11+ times)
and experimentation with other illicit drugs (OIDs) as well as cannabis abuse/dependence (A/D)
problems and OID A/D problems in Australian female and male same-sex twin pairs
Experimentation
No.
1
2
3
4
5
6
7
8
9
10
11
12
13

Early use

Repeated use

A/D problems

Model

Female

Male

Female

Male

Female

Male

Female

Male

Chance
Alternate forms
Random multiformity
Random multiformity of cannabis
Random multiformity of OIDs
Extreme multiformity
Extreme multiformity of cannabis
Extreme multiformity of OIDs
Three independent disorders
Correlated vulnerabilities
Reciprocal liability causation
Unidirectional : cannabis causes OID
Unidirectional : OID causes cannabis

300.6
295.1
58.5
55.9
81.2
x3.9
x6.92
60.9
52.4
x5.1
x7.21
x5.2
13.7

177.9
224.1
35.3
150.9
32.6
0.3
x0.8
12.1
13.5
x5.61
x0.7
x5.22
x4.1

172.7
107.7
42.6
41.3
76.4
9.2
15.5
30.9
33.9
x12.71
x5.22
1.7
24.0

133.2
103.6
36.6
41.1
36.6
x1.2
3.9
15.6
80.0
x11.81
x7.22
x3.1
3.5

506.9
107.5
30.7
28.7
82.7
8.82
13.9
33.7
27.3
7.41
17.2
15.2
36.2

478.6
114.2
52.7
45.9
44.1
3.8
0.6
19.4
59.2
x3.12
x2.4
x4.41
3.2

168.3
49.4
10.5
19.5
10.8
40.5
6.9
12.0
16.2
x3.82
x4.6
x5.91
30.9

126.9
26.6
39.0
35.2
54.3
3.8
2.5
51.7
49.9
x3.22
x4.8
x6.91
x5.8

a

The AIC is an index of both ﬁt and parsimony. The lower (or more negative) the AIC, the better the relative ﬁt of the model.
Numerical superscripts refer to the ranking of models by ﬁt: 1=best-ﬁtting and 2=second best-ﬁt. When more than one submodel of a
model ﬁt equally well, the submodel with the lower AIC was selected for the relative ranking of AICs. Analyses used 487 monozygotic (MZ)
male, 696 MZ female, 387 dizygotic (DZ) male and 506 DZ female complete pairs.

the co-morbidity between cannabis use (experimentation, early and repeated use), cannabis
A/D problems, and experimentation and A/D
problems with OIDs. Genetic correlations across
the cannabis and OID phenotypes were high, as
were correlations between shared environmental
factors inﬂuencing both cannabis and OID
experimentation. Likewise, for the liability causation models, the regression parameter was high,
showing that common underlying liabilities
were largely contributing to co-morbid use and
problems with cannabis and OIDs. In women,
the extreme multiformity of cannabis model ﬁt
better than the correlated vulnerabilities model
for co-morbid experimentation. This model also
ﬁt well for co-morbid repeated cannabis use and
OID experimentation in women.
To illustrate these ﬁndings, we describe in
detail the results for experimentation with cannabis and OIDs. The best-ﬁtting model in males
was the correlated vulnerabilities model (AIC
x5.6) followed by the unidirectional causation
of cannabis model (AIC x5.2). Genetic inﬂuences on OID experimentation were shared
(Rg=0.57, 0.572=33 % overlap) with cannabis
experimentation, as were the shared (Rc=0.98,
0.982=96 % overlap) and unique environmental
(Re=0.40, 0.402=16% overlap) inﬂuences ;
however only shared environmental factors

seemed to have less of a speciﬁc inﬂuence on
OID experimentation. The second-best-ﬁtting
model was the unidirectional causation model,
which suggests that a signiﬁcant proportion of
the total variance in OID experimentation was
shared with cannabis experimentation (b=
0.715). In female twins, the reciprocal causation
model (AIC x7.2) and the extreme multiformity of cannabis model (AIC x6.9) ﬁt
marginally better than the correlated liabilities
model (Table 3). The reciprocal causation
model showed a positive association between
cannabis experimentation and OID experimentation, as well as a negative reciprocal path.
The second-best-ﬁtting model was the extreme
multiformity of cannabis model, which was also
the third-best-ﬁtting model in men. According
to this model (Model 7 : third-best-ﬁt in men),
26 % of the women who were high-risk cannabis
users were at an independent increased risk for
using OIDs.
DISCUSSION
We sought to explore the potential mechanisms
for the co-morbid use (experimentation, early
use and repeated use) of, and problems with,
cannabis and OIDs. Although we did not ﬁnd
unequivocal evidence for a single best-ﬁtting

Table 4.

Standardized parameter estimates for the best-ﬁtting Neale–Kendler model in female and male adult Australian twins

Variable 1

Variable 2

2

Variable 2
2

2

Model
no.

a
(95 % CI)

c
(95 % CI)

e
(95 % CI)

a
(95 % CI)

c2
(95 % CI)

e2
(95 % CI)

Rg

Rc

Re

b
b1=0.79
(0.53–1.00) ;
b2=x0.31
(x0.33 to x0.05)
—

Female twins
Experimentation
with cannabis

OID
experimentation

11

0.44
(0.41–0.49)

0.28
(0.26–0.35)

0.28
(0.20–0.29)

0.31
(0.29–0.36)

0.18
(0.13–0.21)

0.51
(0.44–0.55)

—

—

—

Early
cannabis use
Repeated
cannabis use
Cannabis A/D
problems

OID
experimentation
OID
experimentation
OID A/D
problems

10

0.44
(0.40–0.47)
0.58
(0.36–0.60)
0.55
(0.30–0.63)

0.30
(0.28–0.35)
0.17
(0.02–0.36)
0.16
(0.11–0.19)

0.26
(0.23–0.27)
0.25
(0.20–0.27)
0.29
(0.20–0.31)

0.39
(0.31–0.41)
0.30
(0.15–0.55)
0.40
(0.32–0.42)

0.21
(0.19–0.40)
0.28
(0.15–0.38)
0.19
(0.17–0.23)

0.40
(0.36–0.42)
0.42
(0.36–0.48)
0.41
(0.22–0.43)

0.66
(0.63–0.68)
0.86
(0.64–1.00)
—

0.74
(0.64–0.74)
0.85
(0.50–0.93)
—

0.10
(0.07–0.12)
0.60
(0.48–0.70)
—

Male twins
Experimentation
with cannabis
Early
cannabis use
Repeated
cannabis use
Cannabis A/D
problems

OID
experimentation
OID
experimentation
OID
experimentation
OID A/D
problems

10

0.48
(0.46–0.50)
0.44
(0.40–0.47)
0.60
(0.30–0.62)
0.68
(0.65–0.69)

0.22
(0.12–0.41)
0.30
(0.28–0.35)
0.16
(0.16–0.43)
0.14
(0.12–0.14)

0.30
(0.28–0.31)
0.26
(0.23–0.27)
0.24
(0.18–0.27)
0.18
(0.16–0.19)

0.35
(0.33–0.55)
0.39
(0.31–0.41)
0.29
(0.24–0.41)
0.67
(0.64–0.70)

0.26
(0.23–0.46)
0.21
(0.19–0.40)
0.35
(0.07–0.56)
0.02
(0.00–0.04)

0.39
(0.28–0.40)
0.40
(0.36–0.42)
0.36
(0.34–0.45)
0.31
(0.22–0.33)

0.57
(0.29–0.51)
0.66
(0.63–0.68)
—

0.98
(0.59–1.00)
0.74
(0.64–0.74)
—

0.40
(0.29–0.42)
0.10
(0.07–0.12)
—

—

—

—

10
12

10
12
12

—
0.60
(0.43–0.83)
—
—
0.78
(0.72–0.81)
0.35
(0.21–0.52)

CI, conﬁdence interval ; OID, other illicit drug ; A/D, abuse/dependence.
Model no. refers to number for best-ﬁtting model (see Table 1, which describes each model, and Table 3, which reports the Akaike ﬁt criterion or AIC). Rg, Rc and Re refer to additive genetic, shared
environmental and unique environmental overlap, respectively (shown if best-ﬁtting model was correlated liabilities, Model 10). b refers to the unsquared estimate of the liability causal path (shown if
best-ﬁtting model was a liability causation model, Models 11–13).
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Variable 1
2
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model, our results suggest that overlapping genetic and environmental factors probably play a
signiﬁcant role in the co-occurrence of cannabis
and OID use and misuse. However, strong evidence, across males and females, was also found
for a model where the liability to experiment with
cannabis, or use of it at an early age or repeatedly, had a causal inﬂuence on the liability to
experiment with OIDs. In women, we also found
evidence for a ‘gateway’ model, where high-risk
cannabis experimenters or repeated users were
at increased risk for experimenting with OIDs
irrespective of their original liability to do so.
Thus, an accrual of evidence in support of
the correlated vulnerabilities model, including
evidence from our present study of Australian
twins, suggests that cannabis use, including
experimentation, early and repeated use, and
OID experimentation, as well as A/D problems
with cannabis and OIDs, are associated, across
gender and cultures (Australian and US
samples), due to genetic, shared and unique
environmental factors that jointly contribute to
the vulnerability to use and misuse these drug
classes. These genetic factors may be genes for
impulse-disinhibition (e.g. dopaminergic receptors for novelty seeking) (Bardo et al. 1996 ;
Miles et al. 2001; Kluger et al. 2002 ; Schinka et
al. 2002 ; Agrawal et al. 2004 a), while the environmental factors may refer to negligent parenting (shared environmental) (Burt et al. 2003 ;
Walden et al. 2004), coercive peer inﬂuences
(Simons-Morton et al. 1999 ; Kobus, 2003; Lee
& Tak, 2005), or childhood sexual or physical
abuse (could be shared or unshared across
members of twin pairs, i.e. C or E) (Kendler
et al. 2000). Overall, a correlated vulnerabilities
model is congruent with the Problem Behavior
Theory (Jessor & Jessor, 1977). According to
this theory, deviant behaviors, including illicit
drug use and conduct problems, possibly with
an early age of onset, cluster in certain individuals due to a general proneness to problem/
deviant behaviors (Donovan & Jessor, 1985 ;
Jessor, 1991).
The reciprocal and unidirectional causation
models were also supported by our analyses.
These models, especially in the absence of
multiwave data, do not infer true causality. The
total variance in one trait is regressed on the
total variance in the other trait and a positive
regression path implies that the liability in

OID experimentation is partly shared with the
liability to cannabis experimentation. Therefore,
the liability causation models are more similar
to the correlated vulnerabilities model and
may be viewed as a reduced form of the former
approach. In the correlated vulnerabilities
model, each component of variance, A, C and E,
is correlated independently across cannabis and
OID experimentation, whereas in the liability
causation models, the total variance in cannabis
experimentation is regressed on the total variance in OID experimentation and vice versa.
Thus, the interpretation of a positive regression
path for the unidirectional causation of the
cannabis model is that a portion of the total
variance in OID experimentation is due to the
variance in cannabis experimentation while the
remainder of the variance in OID experimentation is shaped by genetic and environmental
inﬂuences speciﬁc to it.
The confounding of the correlated vulnerabilities and liability causal models, as seen in
our model-ﬁtting procedure, has been tested
previously, using simulated data, by Rhee et
al. (2004). Using 300 simulated datasets, the
authors pointed out that even when the true
model was a liability causation model, 26–54
times the correlated liabilities model ﬁt the data
best. This ﬁnding and our observations, as well
as data from the original NK manuscript (Neale
& Kendler, 1995), support prior research by
Heath et al. (1993), which tested the validity of
cross-sectional data in discriminating between
direction-of-causation models (Duﬀy & Martin,
1994), especially for two traits with similar
magnitudes of genetic, shared and unique
environmental inﬂuences.
Particularly in female twins, we also found
evidence for a model where high-risk cannabis
experimenters or repeated users were at increased risk for experimenting with OIDs,
despite being below the risk threshold for OID
experimentation (extreme multiformity of cannabis). This increase in risk for OID experimentation is not due to correlated risk factors,
but is instead due to the individual’s cannabis
experimentation alone. One possible explanation for this may be exposure opportunity or
availability, which is proposed as a contributor
to gateway eﬀects (Hall & Lynskey, 2005). It
may be that women of this cohort had less
frequent exposure to cannabis and were
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therefore also less exposed to OIDs, as research
has shown exposure opportunity to OIDs to be
signiﬁcantly greater in cannabis users (Wagner
& Anthony, 2002). Therefore, co-morbid cannabis and OID experimentation and repeated
use may reﬂect greater drug-seeking or deviancy
in this sample of women than in the men. The
multiformity models may be viewed as restricted
forms of a bivariate moderator model (Martin
et al. 1987; Dick et al. 2001 ; Purcell, 2002),
where the A, C and E inﬂuencing cannabis and
OID experimentation are uncorrelated and the
variance in OID experimentation is estimated
freely in individuals who are experimenters (or
high-risk users, if extreme multiformity) versus
those who are not experimenters (including
low-risk users for extreme multiformity) of
cannabis. If the ‘gateway ’ eﬀect is viewed as an
outcome of multiformity, where the liability to
experiment with OIDs varies as a function of
cannabis experimentation, then using adaptations of the multiformity models, we may,
in the future, be able to consolidate features
of the competing correlated liabilities and
‘gateway’ hypotheses.
Overall, our ﬁndings, in conjunction with
previous results (Agrawal et al. 2004 c), suggest
that cannabis and OID use and misuse co-occur
in the population due to common risk factors
(correlated vulnerabilities) or a liability that is,
in part, shared (liability causation). However, as
shown previously with the Virginia sample, a
proportion of those who are high-risk cannabis
users are also at increased risk for OID experimentation, not due to correlated risk factors
but instead due to their cannabis use behavior
itself. This second threshold may reﬂect heterogeneity in the binary construct that we use
for cannabis use. In other words, the upper
threshold (or high-risk threshold) may reﬂect a
subset of cannabis users with earlier onset, or
co-morbid conduct disorder, or negative aﬀect
problems, or even susceptibility to subsequent
dependence. This is possibly why the extreme
multiformity model did not provide as a good a
ﬁt when we examined the co-morbidity between
early cannabis use and OID experimentation or
A/D problems, suggesting that in these models
we may have ‘ captured’ the high-risk behavior.
A more sophisticated approach, however, would
be to modify the NK models to use ordinal
data (e.g. abstain versus early- and late-onset
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cannabis use), with an underlying normal distribution of liability.
The present ﬁndings may be viewed with
certain limitations in mind. First, the results reported here are based on data from a sample of
adult Caucasian twins residing in Australia, and
therefore may not be extrapolated to other age
cohorts and ethnicities. Second, the models were
ﬁtted with certain technical limitations (i.e.
usage of dichotomous outcomes, using only
bivariate models) and, as a consequence, we
may not have explored other potential phenotypic deﬁnitions (repeated use as 11+ times
versus daily use) and mechanisms of association
between cannabis and OID use patterns. Third,
because of the cross-sectional nature of the data,
our deﬁnition of causality and our ability to
detect it may be somewhat limited. Fourth, we
did not have diagnostic assessments of abuse
or dependence, nor did we condition A/D for
prior use. Fifth, we did not explore the relationship between problems with licit and illicit
drugs, where diﬀerent models may ﬁt well (Rhee
et al. 2006). Finally, our inability to clearly
distinguish the correlated vulnerabilities model
from the liability causation and the extreme
multiformity model is probably due to limited
power, which has previously been observed to
contribute to the modest AIC diﬀerences across
non-nested models. However, it should be noted
that a signiﬁcant number of mechanisms, such
as chance, alternate forms, three independent
disorders and random multiformity, could be
clearly eliminated.
The strengths of this study include the large
sample size, extensive model-ﬁtting and use of
multiple indicators of cannabis use behavior.
Most importantly, the current study, in addition
to the correlated vulnerabilities and gateway
models, tests multiple alternative mechanisms
that may contribute to the relationship between
cannabis and OIDs. Therefore, not only do we
replicate important ﬁndings from previous
twin studies but we also add substantively to
this growing body of literature by testing alternate phenotypes for cannabis use, including
experimentation, early and repeated use, which
are both considered to be more accurate markers for subsequent illicit drug involvement than
cannabis experimentation alone.
Although there is overwhelming evidence for
the correlated vulnerabilities model, we cannot

58

A. Agrawal et al.

unequivocally rule out ‘ gateway ’ eﬀects of
cannabis use on the experimentation with
OIDs. This seems to be especially true for the
Australian women in our sample. A similar
pattern of association has also been seen in the
Virginia adult sample. By contrast, the study by
Tsuang et al. (1998) did not ﬁnd evidence for a
genetic gateway model, which they deﬁned as
a reduced correlated liabilities model, where
common genetic and environmental inﬂuences
(or the covariance) across A/D of several classes
of illicit drugs was mediated through cannabis
abuse. This divergence in ﬁndings with Tsuang
and colleagues may be due to several reasons,
such as their use of a male-only sample, the
possibility that their sample of males serving in
the military may have had greater access to illicit
drugs when compared to their civilian counterparts and their interpretation of the gateway
model, which is somewhat diﬀerent from the
ones we test. As pointed out by Morral et al.
(2002 a, b), models are required to examine
whether the ‘ gateway ’ inﬂuence persists even
after accounting for the shared vulnerability to
multiple substance use and misuse. To test this
hypothesis within the framework of the comorbidity models, we would need to adapt the
extreme multiformity model to include overlapping genetic, shared and unique environmental
inﬂuences.
Hall & Lynksey (2005) recently reviewed
mechanisms by which cannabis use may be
associated with patterns of OID use. Broadly
deﬁned, these mechanisms may be correlative,
causal or both. As discussed previously, a correlative relationship refers to the inﬂuence of
common risk factors, which may be measured
(e.g. novelty-seeking scores) or latent (e.g. genes
inﬂuencing novelty seeking), that inﬂuence
experimentation with cannabis and OIDs.
Causal inﬂuences, however, may be social
(e.g. drug availability) or pharmacological (e.g.
cross-sensitization of neuroreceptors). Cannabis
may be a gateway drug because it introduces
users to a provider (peers or black-marketeer)
(Pacula et al. 2001) who eventually may also
become the source for OIDs. Cannabis may also
be a gateway drug if neurobiological changes in
cannabis users result in increased drug-seeking
behavior or sensitivity to OIDs, as supported by
some animal studies (Tanda et al. 1997). Correlative and causal models are not mutually

exclusive (Agrawal & Lynskey, 2006). Although
it is likely that use or misuse of multiple illegal
drugs, including cannabis, is in fair part due
to common genetic and environmental factors,
even after controlling for these correlative inﬂuences, some causal inﬂuences, which are
more likely to be social than pharmacological,
plausibly mediate some of the residual inﬂuence
of cannabis use on OID experimentation and
misuse.
What are the public health implications of
our ﬁndings? If cannabis use has a purely causal
impact on experimenting with OIDs, then
targeting prevention eﬀorts at reducing cannabis experimentation alone will result in a drastic
reduction in subsequent OID experimentation.
As this is implausible, prevention eﬀorts that
aim to reduce the general level of drug use and
problem behavior in adolescents will be more
eﬀective than an isolated eﬀort to reduce rates of
cannabis use alone. In addition, more research is
needed to characterize the high-risk cannabis
users who are at risk for OID use and possibly
a host of other psychopathology (e.g. childhood psychopathology, early-onset alcohol and
tobacco use) and to examine how a disruptive
home environment and negative peer aﬃliations,
which inextricably feed back on each other,
inﬂuence their high-risk status. If there exists
a ‘ gateway ’ eﬀect, it is unlikely to begin with
exposure to cannabis, and the identiﬁcation of
endophenotypes will greatly assist in clarifying
the nature of the association between cannabis
and OIDs.
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